NASDAQ: CGCCanopy Growth Corp Stock
$0.88+0.00 (+0%)
Updated May 26, 2023
CGC Price
$0.88
Fair Value Price
$0.88
Market Cap
$434.02M
52 Week Low
$0.83
52 Week High
$5.10
P/E
-0.15x
P/B
0.4x
P/S
3.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$331.55M
Earnings
-$2.29B
Gross Margin
-36.1%
Operating Margin
-711.63%
Profit Margin
-712.3%
Debt to Equity
1.11
Operating Cash Flow
-$397M
Beta
1.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGC Overview
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGC ($0.88) is undervalued by 0.83% relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CGC ($0.88) is not significantly undervalued (0.83%) relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CGC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CGC due diligence checks available for Premium users.
Be the first to know about important CGC news, forecast changes, insider trades & much more!
CGC News
Valuation
CGC fair value
Fair Value of CGC stock based on Discounted Cash Flow (DCF)
Price
$0.88
Fair Value
$0.88
Undervalued by
0.49%
CGC ($0.88) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGC ($0.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CGC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CGC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.15x
Industry
14.7x
Market
54.23x
CGC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
1.74x
CGC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGC's financial health
Profit margin
Revenue
$73.9M
Net Income
-$190.9M
Profit Margin
-258.4%
CGC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CGC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.2B
Liabilities
$1.2B
Debt to equity
1.11
CGC's short-term assets ($881.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGC's short-term assets ($881.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CGC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$105.0M
Investing
$98.6M
Financing
-$97.5M
CGC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGC vs Pharmaceutical Stocks
Canopy Growth Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.